Exela Pharma Sciences
As of the edition of 20 October 2026, Exela Pharma Sciences runs 14 drugs, 14 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Total | 14 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Midazolam | none listed | 1 |
| Fentanyl | none listed | 6 |
| Tranexamic acid | none listed | 2 |
| Phenylephrine | none listed | 6 |
| Glycopyrronium | none listed | 10 |
| Pantoprazole | Ends 2027 (exclusivity) | 1 |
| Palonosetron | none listed | 3 |
| Ganciclovir | none listed | 0 |
| Verapamil | none listed | 8 |
| Diltiazem | none listed | 8 |
| Neostigmine | none listed | 1 |
| Ephedrine | none listed | 9 |
| Nitroprusside | none listed | 2 |
| Cysteine | none listed | 0 |
A route B row is one company at one target.